According to the financial news app ZhuTong Finance, the British pharmaceutical giant AstraZeneca (AZN.US) announced that the experimental anti-cancer drug, datopotamab deruxtecan (Dato-DXD), jointly developed with Daiichi Sankyo Co., Ltd., did not prolong the survival of patients in a key breast cancer treatment trial, showing no significant advantage over chemotherapy. In response to this news, AstraZeneca's stock price fell by 1.4% in pre-market trading. The company stated that it will share these trial results with regulatory agencies and discuss whether the drug should be approved for market release.

This study targeted breast cancer patients who were unable to undergo surgical removal or had metastasized, were hormone receptor-positive, had low HER2 expression, or were HER2-negative. Although in the early stages of the trial, datopotamab deruxtecan showed positive signs, such as prolonging patients' progression-free survival, the final results did not meet expectations.

AstraZeneca explained that the trial results may have been interfered with because patients participating in the trial continued to receive other effective treatments after cancer progression. The company also noted that despite only achieving partial positive data in earlier lung cancer trials this month, it is still committed to developing this drug as a treatment option for breast cancer patients.

It is understood that datopotamab deruxtecan is an antibody-drug conjugate (ADC), designed to deliver potent chemotherapy drugs directly to cancer cells in order to kill cancer cells while reducing damage to healthy cells.